title: Polyethylene glycol modification: relevance of improved methodology to tumour targeting.
abstract: Of all the polymers applied to molecule altering structural chemistry, polyethylene glycol (PEG) modification has numerous benefits and relatively few drawbacks. PEG is now increasingly being applied to the problems of tumour targeting, both in the context of the passive targeting of PEG-liposomes and in active targeting strategies using PEGylated anti-tumour antibodies. PEG can also serve as a useful linker molecule between targeting moieties and other agents, including cytotoxic or imaging agents and targeted liposomes. Despite these demonstrated benefits and the level of attention which PEGylation has received, relatively little consideration has been given to two key areas: first, the extent to which the coupling method has an impact on both the functionality of the PEG-adduct and the acquisition of beneficial properties; second, that the impact of PEGylation on biodistribution is complex, thus any attempt to optimise a PEG-peptide or PEG-liposome for a particular task must involve an examination of all the individual facets of the effects of PEGylation. Studies investigating the underlying principles of tumour targeting suggest that current views concerning the optimisation of PEGylated vehicles for tumour localisation need to be re-examined.
authors.affiliation: Molecular Cell Pathology, Royal Free Hospital School of Medicine, London, U.K.
authors.forename: G E
authors.initials: GE
authors.lastname: Francis
authors.forename: C
authors.initials: C
authors.lastname: Delgado
authors.forename: D
authors.initials: D
authors.lastname: Fisher
authors.forename: F
authors.initials: F
authors.lastname: Malik
authors.forename: A K
authors.initials: AK
authors.lastname: Agrawal
mesh_terms: D000917:Antibody Formation; D001665:Binding Sites; D016503:Drug Delivery Systems; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism; D006801:Humans; D008081:Liposomes / Q000378:metabolism; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000648:ultrastructure; D010455:Peptides / Q000378:metabolism; D011092:Polyethylene Glycols / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*; D011506:Proteins / Q000378:metabolism; D011994:Recombinant Proteins / Q000378:metabolism; D013329:Structure-Activity Relationship; D014018:Tissue Distribution
chemical_list: D008081:Liposomes; D010455:Peptides; D011506:Proteins; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D016178:Granulocyte-Macrophage Colony-Stimulating Factor